189 related articles for article (PubMed ID: 37895143)
1. Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.
Zhang Y; Zhang C; Li K; Deng J; Liu H; Lai G; Xie B; Zhong X
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895143
[TBL] [Abstract][Full Text] [Related]
2. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
3. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
5. Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.
Ji D; Zhong R; Fan S
Biomed Res Int; 2022; 2022():8740408. PubMed ID: 35647181
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
7. Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma.
Shen C; Wang Y
Arch Med Res; 2023 Jan; 54(1):45-55. PubMed ID: 36528469
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma.
Wu K; Liu Z; Liang J; Zhu Y; Wang X; Li X
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793855
[TBL] [Abstract][Full Text] [Related]
10. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
11. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
12. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
13. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
14. Identification and Verification of Immune-Related Genes Prognostic Signature Based on ssGSEA for Adrenocortical Carcinoma (ACC).
Yuan K; Zeng R; Deng P; Zhang A; Liu H; Wang N; Tang Y; Yin Z; Liu H
Int J Gen Med; 2022; 15():1471-1483. PubMed ID: 35210821
[TBL] [Abstract][Full Text] [Related]
15. Identification of prognostic metabolic genes in adrenocortical carcinoma and establishment of a prognostic nomogram: A bioinformatic study.
Chen Q; Ren Z; Liu D; Jin Z; Wang X; Zhang R; Liu Q; Cheng W
Medicine (Baltimore); 2021 Dec; 100(50):e27864. PubMed ID: 34918636
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.
Xu W; Li H; Hameed Y; Abdel-Maksoud MA; Almutairi SM; Mubarak A; Aufy M; Alturaiki W; Alshalani AJ; Mahmoud AM; Li C
Oncol Res; 2023; 31(5):819-831. PubMed ID: 37547754
[TBL] [Abstract][Full Text] [Related]
17. The Characteristics of Tumor Microenvironment Predict Survival and Response to Immunotherapy in Adrenocortical Carcinomas.
Lai G; Liu H; Deng J; Li K; Zhang C; Zhong X; Xie B
Cells; 2023 Feb; 12(5):. PubMed ID: 36899891
[TBL] [Abstract][Full Text] [Related]
18. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
19. Identification of immune-related biomarkers in adrenocortical carcinoma: Immune-related biomarkers for ACC.
Peng Y; Song Y; Ding J; Li N; Zhang Z; Wang H
Int Immunopharmacol; 2020 Nov; 88():106930. PubMed ID: 32919215
[TBL] [Abstract][Full Text] [Related]
20. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
